Skip to main content
. Author manuscript; available in PMC: 2015 Jul 16.
Published in final edited form as: Vaccine. 2014 Jun 2;32(33):4171–4178. doi: 10.1016/j.vaccine.2014.05.044

Table 4a.

HPV series initiated in conjunction with receipt of Tdap and/or menmgococcal vaccine, boys ages 11–13

Number (%) receiving HPV vaccine/Number of opportunities† (%)
Entire State Intervention counties Control counties p-value for chi-square of intervention vs. control
6 mo. Pre-intervention 3788/17002 (22.3%) 484/1842 (26.3%) 114/510 (22.4%) 0.07
During intervention 6743/29183 (23.1%) 981/3313 (29.6%) 204/1085 (18.8%) <.0001
6 mo. Post-intervention 5779/20446 (28.3) 776/2392 (32.4%) 216/784 (27.6%) 0.01
†

An “opportunity” is defined as any administration of Tdap and/or meningococcal vaccine on a boy ages 11–13 who had not yet started the HPV series.